Company Overview
Azenta, Inc. operates within the healthcare sector, specifically focusing on the medical instruments and supplies industry by providing biological and chemical compound sample exploration and management solutions to the life sciences industry across the United States, China, the United Kingdom, the rest of Europe, the Asia Pacific region, and internationally. The company functions through two primary segments: Sample Management Solutions and Multiomics, offering essential infrastructure for research and development activities in biotechnology and pharmaceuticals. This entity maintains a significant operational scale with a market capitalization of $981.57M, generating annual revenue of $595.03M, and employing a workforce of 3,000 individuals. These valuation and revenue figures indicate that Azenta has established itself as a substantial player in the specialized supply chain for life sciences, commanding a significant market presence that supports its extensive global distribution network.
Financial Health
The company reported a trailing twelve-month revenue of $595.03M, which resulted in a net income of $26.34M and an EBITDA of $37.33M. The substantial gap between the $595.03M in revenue and the $26.34M in net income reveals a cost structure where operating expenses and taxes consume a considerable portion of gross sales before reaching the bottom line. Despite the lower net income, the business demonstrates strong cash generation capabilities with a free cash flow of $108.52M, which provides the organization with significant financial flexibility to fund operations, service debt, or pursue strategic initiatives without relying on external financing. Profitability metrics show a gross margin of 44.6%, indicating a pricing power or cost advantage in sourcing biological compounds, while an operating margin of -4.1% and a profit margin of -10.1% suggest that high administrative costs or one-time charges are currently pressuring the bottom line below the gross profitability level. The balance sheet displays a conservative stance regarding leverage, holding $409.66M in cash against only $54.46M in debt, resulting in a debt-to-equity ratio of 3.18. Although the debt-to-equity ratio numerically exceeds one, the overwhelming liquidity position ensures the company is not constrained by short-term solvency issues. Liquidity is further supported by a current ratio of 2.92, which indicates that the company holds nearly three times the value of current assets relative to its current liabilities, ensuring robust short-term liquidity. Return on equity stands at 1.5% and return on assets is -0.6%, revealing that the company is currently generating minimal returns on shareholder capital and a slight loss on the total asset base relative to the capital employed.
Valuation Assessment
Valuation multiples for Azenta, Inc. show a trailing P/E ratio of 36.74 compared to a forward P/E of 20.10. The significant difference between the trailing P/E of 36.74 and the forward P/E of 20.10 implies that the market expects earnings to expand substantially in the future to justify the current high multiple, or that current earnings are suppressed by temporary factors. The price-to-book ratio is 0.57, which indicates that the market is valuing the company at less than its book value, suggesting no premium over the net asset value held by the firm. Alternative valuation metrics include a price-to-sales ratio of 1.65 and an EV/EBITDA of 16.78, which provide context on how the market values the company relative to its sales revenue and cash earnings before interest, taxes, depreciation, and amortization. Regarding trading range, the 52-week high is $41.73 and the 52-week low is $19.94. Without a specific current share price provided in the available facts, the precise percentage distance from the 52-week high cannot be calculated, but the range defines the volatility corridor within which the stock has traded over the past year. The stock exhibits a beta of 1.40, which means the share price is expected to be 40% more volatile than the broader market, reflecting higher sensitivity to market movements.
Growth & Income
Revenue growth over the last year was 0.8%, while earnings growth for the year is listed as N/A. The absence of reported earnings growth data prevents a direct comparison between earnings and revenue trajectories, but the modest revenue growth of 0.8% suggests a mature or stabilizing top-line performance in a competitive medical supply environment. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute profits to shareholders, indicating that earnings are retained within the business to fund operations and growth initiatives rather than being paid out. The overall growth and income profile is characterized by a lack of dividend income, relying instead on potential capital appreciation and the reinvestment of cash flows generated from its substantial free cash flow position.